Shanghai Junshi Biosciences Co (HKSE:01877) EV-to-EBIT : -20.59 (As of May. 13, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Shanghai Junshi Biosciences Co's Enterprise Value is HK$26,039.9 Mil. Shanghai Junshi Biosciences Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,264.8 Mil. Therefore, Shanghai Junshi Biosciences Co's EV-to-EBIT for today is -20.59.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's EV-to-EBIT or its related term are showing as below:

HKSE:01877' s EV-to-EBIT Range Over the Past 10 Years
Min: -50.05 Med: -8.38 Max: -4.33
Current: -20.59

During the past 8 years, the highest EV-to-EBIT of Shanghai Junshi Biosciences Co was -4.33. The lowest was -50.05. And the median was -8.38.

HKSE:01877's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs HKSE:01877: -20.59

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Shanghai Junshi Biosciences Co's Enterprise Value for the quarter that ended in Mar. 2024 was HK$8,105.2 Mil. Shanghai Junshi Biosciences Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was HK$-1,264.8 Mil. Shanghai Junshi Biosciences Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -15.61%.

Shanghai Junshi Biosciences Co EV-to-EBIT Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co EV-to-EBIT Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-24.62

-23.59

-71.19

-14.48

-6.38

Shanghai Junshi Biosciences Co Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial														-10.42	-6.01	-6.49	-6.38	-6.41

Competitive Comparison of Shanghai Junshi Biosciences Co's EV-to-EBIT

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Junshi Biosciences Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's EV-to-EBIT falls into.

Shanghai Junshi Biosciences Co EV-to-EBIT Calculation

Shanghai Junshi Biosciences Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	26039.864	/	-1264.84
	=	-20.59

Shanghai Junshi Biosciences Co's current Enterprise Value is HK$26,039.9 Mil.
Shanghai Junshi Biosciences Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,264.8 Mil.

Shanghai Junshi Biosciences Co (HKSE:01877) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Shanghai Junshi Biosciences Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-1264.84	/	8105.2003
	=	-15.61 %

Shanghai Junshi Biosciences Co's Enterprise Value for the quarter that ended in Mar. 2024 was HK$8,105.2 Mil.
Shanghai Junshi Biosciences Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,264.8 Mil.

Shanghai Junshi Biosciences Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

8SJ:Germany 688180:China

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines